Home
Research
Treatments
Business
Management
Contact Us
Visceral Fat Control is a start-up family-owned biotechnological company presently focusing on the following research areas:
1. Determine the mechanism by which low doses of the non-toxic human protein, ZKPr1, reduce excess visceral fat in obese and non-obese mice by ~75-90%.
2. Explore how ZKPr1 can be utilized using it either as a stand-alone treatment of normal-weight younger and older adult people with excess visceral fat, or as an add-on treatment along with weight reducing drugs to greatly reduce excess visceral fat in obese people of any age.
3. Use ZKPr1 and another low dose non-toxic human protein, ZKPr2, which also specifically reduces visceral fat in suitable mouse models to examine how extensive and specific visceral fat reduction by both proteins affects various health disorders and conditions including life expectancy. Such studies are expected to provide strong leads for drug development and allow significant savings in research costs. [Observational human studies often do not reliably prove casual relationships between excess visceral fat and human disorders because of the many confounding factors that may be involved.
